Stock Locations

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

124643-35-2Abiraterone Related Compound 2 (Prasterone Triflate)

● In Stock

Catalogue No.:	VL830009
CAS No.:	124643-35-2
Mol. Formula:	C20H27F3O4S
Mol. Weight:	420.49 g/mol

Request a quote

Add to RFQ list

Additional information on CAS 124643-35-2

Parent drug

Abiraterone

IUPAC Name

(3S, 8R, 9S, 10R, 13S, 14S)-3-hydroxy-10, 13-dimethyl-2, 3, 4, 7, 8, 9, 10, 11, 12, 13, 14, 15-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl trifluoromethanesulfonate

Pharmacopoeial Synonyms

N/A

Other Synonyms

3Î²-Hydroxyandrosta-5,16-diene-17-yl trifluoromethanesulfonate

Smiles

O=S(C(F)(F)F)(OC1=CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)=O

InChI

InChI=1S/C20H27F3O4S/c1-18-9-7-13(24)11-12(18)3-4-14-15-5-6-17(19(15,2)10-8-16(14)18)27-28(25,26)20(21,22)23/h3,6,13-16,24H,4-5,7-11H2,1-2H3/t13-,14-,15-,16-,18-,19-/m0/s1

Description

Abiraterone Related Compound 2 (Prasterone Triflate) is a meticulously characterized reference material that complies with rigorous regulatory requirements, including those defined by USP, EMA, JP, and BP. This product plays a crucial role in Abbreviated New Drug Applications (ANDA), New Drug Applications (NDA), and the commercial manufacturing of Abiraterone. It is further supported by a detailed Structure Elucidation Report (SER), ensuring high accuracy and reliability across a broad range of analytical applications. Abiraterone Related Compound 2 (Prasterone Triflate) is a steroidal compound with antiandrogen activity. Abiraterone is used to treat metastatic, castration-resistant prostate cancer mainly in patients who have undergone chemotherapy. Abiraterone acetate is a prodrug of aberaterone.

References

Works Cited de Bono, Johann S., et al. â€œAbiraterone and Increased Survival in Metastatic Prostate Cancer.â€ New England Journal of Medicine, vol. 364, no. 21, 26 May 2011, pp. 1995â€“2005, 10.1056/nejmoa1014618.